Company news
Neurizon Therapeutics Limited news in 2020
Neurizon Therapeutics Limited's news releases, calls and decks from 2020, newest first.
PAA Commences Manufacture of GMP-Grade MPL for Human Trials
December 22, 2020
PharmAust to Commence Phase IIb Dog Cancer Trial
December 21, 2020
ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
September 29, 2020
PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
September 23, 2020
PAA awarded grant for Phase I trial in Motor Neurone Disease
September 20, 2020
PharmAust Shareholder Update
September 13, 2020
Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
September 8, 2020
Elanco Option Update
September 8, 2020
Epichem in partnership to develop waste into fuel technology
August 31, 2020
Appendix 4E & Preliminary Final Report
August 30, 2020
Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells
August 24, 2020
Reinstatement to Official Quotation
June 17, 2020
Confirmation of Preliminary COVID-19 Results
June 17, 2020
Voluntary Suspension
June 14, 2020
Virtual Investor Briefing Presentation
June 9, 2020
Preliminary Positive Results for the Treatment of SARS-CoV-2
June 3, 2020
Suspension from Official Quotation
June 2, 2020
Monepantel Trial Achieves Successful Anti-Cancer Outcome
May 11, 2020
PharmAust to Evaluate Monepantel on COVID-19
April 16, 2020
Brisbane Animal Hospital Joins Phase II Dog Cancer Trial
March 2, 2020
PharmAust Receives $700k R&D Tax Incentive Refund
January 14, 2020
Epichem Awarded One-Year Contract Extension from DNDi
January 7, 2020
Epichem client gives notice to end contract in February 2020
January 6, 2020
Decks in 2020
- Epichem — Investor Presentation (July 2020)
Investor deck · 27 slides · July 2020
- Investor Presentation (June 2020)
Investor deck · 17 slides · Jun 10, 2020
- PharmAust — Investor Presentation (June 2020)
Investor deck · 16 slides · June 2020